Form 4: Paychex Director Acquires New Equity Awards Under Incentive Plan
Insider Transaction Report
Paychex Inc. Director Tom Bonadio reported the acquisition of 164 restricted stock units and 670 stock options, effective July 15, 2025, as part of the company's incentive plan.
Summary
- Director Tom Bonadio acquired 164 shares of common stock as restricted stock units (RSUs) at a price of $0, subject to vesting, pursuant to the Amended and Restated 2002 Stock Incentive Plan.
- He also acquired 670 stock options with an exercise price of $140.68. These options become exercisable on July 15, 2026, and expire on July 14, 2035.
- Following these transactions, Bonadio beneficially owns a total of 19,779 shares of common stock.
- The filing also details existing stock option holdings, including 4,404 options at $61.47, 9,615 at $57.20, 8,641 at $70.37, 7,929 at $85.33, 5,793 at $73.53, 5,075 at $112.67, 3,027 at $115.00, 3,382 at $120.86, and 3,351 at $121.63.
Sentiment
Score: 7
Explanation: The filing indicates a routine equity grant to a director, which is a positive sign of continued alignment between management and shareholder interests. There are no negative financial implications for the company, and the associated Power of Attorney is a standard administrative document.
Positives
- Acquisition of 164 restricted stock units at no cost, indicating a grant as part of compensation.
- Grant of 670 stock options, providing future potential upside if the stock price increases above the exercise price of $140.68.
- The transactions are part of the Amended and Restated 2002 Stock Incentive Plan, aligning director incentives with shareholder interests.
Risks
- The Power of Attorney authorizes attorneys-in-fact to act without independent verification of information provided to them.
- Neither the company nor the attorneys-in-fact assume liability for the undersigned's compliance with Exchange Act requirements, any failure to comply, or profit disgorgement under Section 16(b) of the Exchange Act.
- The Power of Attorney does not relieve the undersigned from personal responsibility for compliance with Exchange Act obligations, including Section 16 reporting requirements.
Future Outlook
The document details future vesting and exercisability dates for equity awards, indicating a long-term incentive structure for the director.
Industry Context
This filing is a routine disclosure of insider transactions, common for publicly traded companies like Paychex, which operates in the human capital management and payroll services industry. Such equity grants are standard practice for director compensation, aligning their interests with long-term company performance.
Comparison to Industry Standards
- Equity grants to directors, including restricted stock units and stock options, are a common form of compensation across various industries, including the financial and business services sector where Paychex operates.
- The specific number of shares and options granted would typically be benchmarked against peer companies in terms of director compensation packages, considering company size, performance, and market capitalization. For example, similar practices are observed in companies like ADP (Automatic Data Processing) or Ceridian HCM Holding Inc., which are direct competitors in the payroll and HR services space.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Authorization of Power of Attorney | Thomas Bonadio granted a Limited Power of Attorney to Prabha S. Bhandari and Robert L. Schrader to handle his Section 16 reporting obligations (Forms 3, 4, and 5) for Paychex, Inc. securities. | August 1, 2024 | This is a standard administrative measure to streamline compliance with SEC reporting requirements for insiders, ensuring timely and accurate filings. It does not alter the director's underlying responsibilities or liabilities. |
Stakeholder Impact
- Shareholders: The equity grants align the director's financial interests with long-term shareholder value creation. The transparency of insider transactions through Form 4 filings provides shareholders with information on director holdings and compensation.
- Employees: No direct impact on employees is specified in this document.
- Customers/Suppliers/Creditors: No direct impact on customers, suppliers, or creditors is specified in this document.
Next Steps
- The newly acquired 670 stock options will become exercisable on July 15, 2026.
- The 164 restricted stock units are subject to vesting, implying future conditions must be met for full ownership.
Key Dates
| Date | Description |
|---|---|
| 01/15/2018 | Date exercisable for 4,404 stock options with an exercise price of $61.47. |
| 07/13/2018 | Date exercisable for 9,615 stock options with an exercise price of $57.20. |
| 07/12/2019 | Date exercisable for 8,641 stock options with an exercise price of $70.37. |
| 07/11/2020 | Date exercisable for 7,929 stock options with an exercise price of $85.33. |
| 07/15/2021 | Date exercisable for 5,793 stock options with an exercise price of $73.53. |
| 07/15/2022 | Date exercisable for 5,075 stock options with an exercise price of $112.67. |
| 07/15/2023 | Date exercisable for 3,027 stock options with an exercise price of $115.00. |
| 07/15/2024 | Date exercisable for 3,382 stock options with an exercise price of $120.86. |
| 08/01/2024 | Date of execution of the Limited Power of Attorney by Thomas Bonadio. |
| 07/15/2025 | Transaction date for the acquisition of 164 restricted stock units and 670 stock options. |
| 07/15/2025 | Date exercisable for 3,351 stock options with an exercise price of $121.63. |
| 07/17/2025 | Signature date of the reporting person's attorney-in-fact for the Form 4 filing. |
| 07/15/2026 | Date exercisable for 670 newly acquired stock options with an exercise price of $140.68. |
| 10/28/2026 | Expiration date of Notary Public's commission for Dana L. Bolia. |
| 01/14/2027 | Expiration date for 4,404 stock options with an exercise price of $61.47. |
| 07/12/2027 | Expiration date for 9,615 stock options with an exercise price of $57.20. |
| 07/11/2028 | Expiration date for 8,641 stock options with an exercise price of $70.37. |
| 07/10/2029 | Expiration date for 7,929 stock options with an exercise price of $85.33. |
| 07/14/2030 | Expiration date for 5,793 stock options with an exercise price of $73.53. |
| 07/14/2031 | Expiration date for 5,075 stock options with an exercise price of $112.67. |
| 07/14/2032 | Expiration date for 3,027 stock options with an exercise price of $115.00. |
| 07/14/2033 | Expiration date for 3,382 stock options with an exercise price of $120.86. |
| 07/14/2034 | Expiration date for 3,351 stock options with an exercise price of $121.63. |
| 07/14/2035 | Expiration date for 670 newly acquired stock options with an exercise price of $140.68. |
Recommendation
holdKeywords
Paychex Inc, PAYX, SEC Form 4, Insider Trading, Stock Options, Restricted Stock Units, Director Compensation, Equity Grant, Executive Compensation, Corporate Governance, Section 16, Insider Filings
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.